Published by Ministry of Health, Labour and Welfare

62

Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this

English translation, the former shall prevail.

Revision of Precautions Pipemidic acid hydrate

September 24, 2019

Therapeutic category

Synthetic antibiotics

Non-proprietary name

Pipemidic acid hydrate

Safety measure Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u> Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Adverse Reactions	Adverse Reactions
Clinically Significant Adverse Reactions	Clinically Significant Adverse Reactions
(N/A)	Tendon disorders such as Achilles tendonitis and tendon rupture
	Tendon disorders such as Achilles tendonitis and tendon rupture
	may occur. If symptoms such as pain, edema, and redness around
	the tendon are observed, administration of this drug should be
	discontinued and appropriate measures should be taken.
	Psychiatric symptoms
	Psychiatric symptoms such as depression and hallucination may
	occur. Patients should be carefully monitored. If any abnormalities
	are observed, administration of this drug should be discontinued
	and appropriate measures should be taken.

N/A: Not Applicable, because the section is not included in the current package insert.

Note: Pipemidic acid hydrate is designated as a drug requiring preparation of a Drug Guide for Patients.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>